Group 1: Financial Performance - Beiterui's gross profit margin is higher than competitors like Xiamen Tungsten and Dingsheng Technology due to a complete industrial chain and a focus on high-end products [2] - The expected gross margin for lithium iron phosphate is around 20%, while for anode materials, it is between 25% and 30% [4] Group 2: Production Capacity - The production capacity ratio of natural graphite to artificial graphite is approximately 2:1 [2] - Beiterui's lithium iron phosphate production is currently at full capacity, with future expansion dependent on market conditions [3] Group 3: Market Trends - The global market for 3C batteries remains larger and more stable than for power batteries, impacting sales from companies like Panasonic and Samsung [3] - Prices for both anode and cathode materials have decreased in the first half of the year, but future trends are uncertain due to rising industrial material costs [3] Group 4: Industry Position - Beiterui holds over 50% of the global market share in the anode materials sector, alongside companies like Hitachi Chemical and Mitsubishi Chemical [4] - The barriers to entry in the anode materials industry are well established, while the cathode materials sector remains fragmented [4] Group 5: Research and Development - The number of R&D personnel for anode materials exceeds that for cathode materials, with an average investment recovery period of around three years [4] - Beiterui is exploring new applications for carbon materials in future battery systems, particularly solid-state batteries [4]

Revenue and Profit - Revenue for Q3 2022 reached ¥8,968,183,216.76, an increase of 116.33% year-over-year, while year-to-date revenue was ¥22,479,591,306.31, up 84.77% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥152,340,142.25, a decrease of 28.19% year-over-year, with year-to-date net profit at ¥575,535,984.92, down 35.52%[3] - Net profit attributable to shareholders decreased by 35.52% to ¥575,535,984.92, mainly due to last year's substantial investment gains from subsidiary disposals[7] - The company reported a total profit of ¥1,858,685,920.06, slightly down from ¥1,904,200,888.16 in the previous year[20] - The total comprehensive income for the period attributable to the parent company was CNY 603,222,583.20, a decrease of 32.3% compared to CNY 890,428,766.25 in the previous period[21] Cash Flow - The company reported a significant increase in cash flow from operating activities, with a year-to-date net cash flow of -¥228,054,074.04, reflecting a decline of 172.44% compared to the previous year[3] - Net cash flow from operating activities showed a significant decline of 172.44%, resulting in a net outflow of ¥228,054,074.04, driven by increased payments for raw materials and processing fees[7] - Cash flow from investing activities experienced a drastic decline of 600.38%, with a net outflow of ¥3,649,689,361.48 due to increased fixed asset investments for capacity expansion[7] - Cash inflow from financing activities was CNY 12,409,939,796.56, significantly higher than CNY 5,465,694,174.34 in the previous period[23] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥49,596,205,059.71, representing a 33.78% increase from the end of the previous year[3] - Total liabilities increased to ¥31,574,038,909.36, compared to ¥21,414,358,734.26 in the previous year, reflecting a growth of 47.4%[18] - The company’s total liabilities increased, with short-term borrowings rising by 34.59% to ¥7,554,462,158.92, driven by business expansion[6] - Non-current liabilities totaled ¥8,370,292,220.45, up from ¥5,987,258,170.15, marking an increase of 39.9%[18] - The total equity attributable to shareholders of the parent company was ¥8,601,041,179.58, an increase from ¥8,000,289,198.35, representing a growth of 7.5%[18] Research and Development - The company’s R&D expenses for Q3 2022 were ¥1,057,290,408.93, an increase of 104.79% year-over-year, indicating a strong commitment to innovation[6] - Research and development expenses surged to ¥1,057,290,408.93, up 104.5% from ¥516,272,570.49 in the previous year[19] Market and Investment Activities - The company plans to continue expanding its market presence and investing in R&D to support future growth initiatives[6] - Betterray signed a cooperation agreement to invest in a lithium battery anode material integrated base project with an annual production capacity of 200,000 tons in Dali, Yunnan[12] - Betterray plans to issue up to 218,423,767 shares, raising a total of no more than 500 million yuan[14] - Betterray and Stellar Investment signed a joint venture agreement for an integrated project with an annual production capacity of 80,000 tons of new energy lithium battery anode materials in Indonesia[14] - Betterray signed a strategic cooperation framework agreement with Zhongwei New Materials to collaborate in various fields including precursor product development and overseas mineral resource development[13] Inventory and Receivables - Trade receivables rose by 77.32% to ¥5,970,361,497.56, reflecting the significant revenue growth during the period[5] - Betterray's accounts receivable increased to approximately 5.97 billion yuan, up from 3.37 billion yuan, representing a growth of about 77.5%[15] - Inventory increased to approximately 13.17 billion yuan, up from 10.14 billion yuan, reflecting a growth of about 30%[16] Operating Costs - The company’s gross profit margin was impacted by rising costs, with operating costs increasing by 106.88% to ¥17,798,253,838.79 due to heightened demand in the battery materials market[6] - The company’s operating costs increased to ¥20,945,941,352.10, up from ¥11,019,287,759.11, reflecting an increase of 90.0%[19] Shareholder Information - The company’s major shareholders include Shaoguan High-tech Enterprise Management Co., Ltd. with a 15.04% stake and Shenzhen Chengxing Investment Co., Ltd. with a 13.72% stake[9]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 13.51 billion, representing a 68.45% increase compared to CNY 8.02 billion in the same period last year[11]. - The net profit attributable to shareholders of the listed company was CNY 423.20 million, a decrease of 37.80% from CNY 680.43 million year-on-year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 429.37 million, an increase of 62.61% compared to CNY 264.06 million in the previous year[11]. - The net cash flow from operating activities was negative CNY 218.06 million, a decline of 232.24% from a positive CNY 164.90 million in the same period last year[11]. - The total assets at the end of the reporting period were CNY 45.22 billion, an increase of 21.97% from CNY 37.07 billion at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were CNY 8.40 billion, up 4.96% from CNY 8.00 billion at the end of the previous year[11]. - The basic earnings per share decreased to CNY 0.1641, down 37.79% from CNY 0.2638 in the same period last year[11]. - The diluted earnings per share also decreased to CNY 0.1641, reflecting the same percentage decline as basic earnings per share[11]. - The weighted average return on equity was 5.14%, down 4.25% from 9.39% in the previous year[11]. - The company achieved total operating revenue of CNY 1,353,163.66 million, a year-on-year increase of 68.13%[22]. - The company's net profit attributable to shareholders decreased by 37.80% to CNY 42,319.58 million, while the net profit excluding non-recurring gains and losses increased by 62.61% to CNY 42,937.30 million[22]. Sector Performance - The company operates in high-tech industries, biomedicine, real estate, and other sectors, focusing on new materials and new energy vehicles[15]. - The biomedicine sector is increasingly important, driven by rising health awareness and demand for healthcare products, with a focus on functional health products[16]. - The real estate market is expected to stabilize as government policies support housing demand and promote long-term rental markets[16]. - The company’s subsidiary, Beiterui, is a leading global producer of lithium-ion battery anode materials, with a complete industrial chain[17]. - The company has over 30 years of experience in the real estate sector, with significant brand influence in the "Jiangnan series" products[18]. - The biomedicine segment includes historical brands like Mayinglong, focusing on traditional medicine and healthcare services[18]. - The high-tech industry segment reported sales revenue of CNY 1,106,715.38 million, a growth of 126.04%, and a total profit of CNY 106,708.94 million, up 11.27%[23]. - The subsidiary Beiterui achieved sales revenue of CNY 1,020,072.39 million, a year-on-year increase of 142.47%, and a net profit of CNY 91,791.26 million, up 25.67%[23]. - The biopharmaceutical segment generated sales revenue of CNY 212,379.82 million, a growth of 11.78%, and a total profit of CNY 33,384.60 million, up 8.74%[24]. - The subsidiary Mayinglong reported sales revenue of CNY 192,775.58 million, a year-on-year increase of 15.54%, and a net profit of CNY 27,193.33 million, up 6.73%[24]. - The real estate segment's sales revenue decreased by 85.74% to CNY 14,988.35 million, with a total profit loss of CNY 3,728.08 million, a decline of 129.90%[25]. Investment and Development - The company is focusing on asset securitization to enhance market competitiveness and achieve rapid development[22]. - The company is actively expanding its production capacity and establishing strategic partnerships for new product development in the high-tech sector[23]. - The company is implementing a strategy of "inventory reduction and sales promotion" in its real estate operations to optimize asset value[25]. - The total investment amount for the current period was ¥296.91 million for the Jiangdong Haoting project in Haikou, Hainan[28]. - The cumulative presale area for the Baonan Jiangnan City project in Tianjin reached 199,134.24 m², with a presale amount of ¥5,022 million[29]. - The average rental rate for the commercial properties in Weihei's Baonanjianan City is 100%[30]. - The company is committed to developing new technologies and enhancing operational capabilities in strategic emerging industries[15]. - The company plans to issue up to 218,423,767 shares, raising a total of no more than 500,000 million CNY[90]. - Bettery entered into a joint venture agreement to develop an integrated project with an annual production capacity of 80,000 tons of new energy lithium battery anode materials in Indonesia[90]. Financial Management - The company is actively involved in military communications and aerospace materials production through its subsidiaries[18]. - The company aims to improve real estate operational efficiency and enhance business performance amid market challenges[16]. - The company is classified as a key pollutant discharge unit, with specific emissions data reported for various pollutants, indicating compliance with environmental standards[59]. - The company has established a management system for foreign exchange derivative trading to mitigate risks associated with foreign exchange and interest rate fluctuations[46]. - The company has not experienced any major legal disputes or penalties during the reporting period[80]. - The company has maintained a clean integrity status with no reported issues regarding its controlling shareholders[80]. - The company has not undergone any credit rating adjustments during the reporting period[105]. - The company has successfully completed the principal and interest payments for its medium-term notes due in 2022, totaling CNY 1.54 billion[105]. - The company maintains a loan repayment rate of 100%, indicating effective debt management[107]. Legal and Compliance - The company is pursuing a lawsuit against Hu Zhiqiang for a total of RMB 19.20 million related to stock repurchase obligations, with a final ruling requiring payment of RMB 9.99 million plus penalties[72]. - The company is involved in a lawsuit regarding a land lease agreement, with claims for RMB 7.99 million in rent and RMB 16.35 million in interest[72]. - The company is seeking RMB 17.46 million in stock transfer payments from Pan Duo Jun, with a court ruling already in place[72]. - The company is pursuing legal action against Xinjiang Pengyuan New Materials Co., Ltd. for a loan principal of RMB 13,937,200 and interest of RMB 15,707,224.40, along with a penalty of RMB 10 million[73]. - The company is actively managing its legal claims and pursuing recovery of debts through litigation and bankruptcy processes[73]. - The company has filed a lawsuit against Ganzhou Xinlei Rare Earth New Materials Co., Ltd. for an investment of RMB 28.5 million and compensation of RMB 2.8 million due to misleading information[73]. - The company is pursuing legal action against Ningbo Fenghua Delang Energy Battery Co., Ltd. for a payment of CNY 23.2051 million and associated penalties[77]. Environmental and Social Responsibility - The company donated 3.43 million yuan worth of medicines to impoverished areas and provided 1.36 million yuan in pandemic prevention materials to Hong Kong[69]. - Betterray New Materials Group purchased over 250,000 yuan in poverty alleviation products to support rural revitalization efforts[69]. - The company actively participated in social welfare activities, including donations to local schools and support for welfare institutions[69]. - The company aims to innovate marketing strategies and develop complementary businesses to enhance operational efficiency and create new profit growth points[54]. - The company has achieved a 100% completion rate in pollution source monitoring in Tianjin[68]. - The company was recognized as a "Blue Card Enterprise" by the Shenzhen Ecological Environment Bureau, indicating a reduction in carbon emissions per product by 0.04 tCO2e/t year-on-year[68]. Risk Management - The company faces risks related to industry policies, technology substitution, and operational risks from upstream and downstream enterprises[52]. - The company emphasizes lean management, cost control, and enhancing product quality to mitigate operational risks[53]. - The company plans to enhance risk control and management in the real estate sector to address market opportunities and policy impacts, focusing on inventory reduction and sales promotion[55]. - The biopharmaceutical industry faces significant policy risks due to regulations such as the two-invoice system and drug price reforms, which may impact operations[54]. - The real estate sector is experiencing financing challenges, with some leading companies facing debt defaults and project delivery delays, affecting normal business operations[55]. Shareholder Information - The total number of shares outstanding is 2,579,213,965, with 98.92% being unrestricted shares[92]. - The company reported a total shareholder equity of 16,680,591,407.56 RMB as of the end of the first half of 2022, an increase from 15,658,836,468.47 RMB at the end of 2021[115]. - The largest shareholder, Shaoguan High-tech Enterprise Management Co., Ltd., holds 15.04% of shares, totaling 387,882,121 shares[95]. - The company did not conduct any repurchase transactions during the reporting period[97]. - The company has not disclosed any other major events or changes in shareholding structure during the reporting period[88].

Financial Performance - The company's operating revenue for Q1 2022 was ¥5,683,423,572.87, representing a 53.56% increase compared to ¥3,701,038,124.21 in the same period last year[3] - Net profit attributable to shareholders decreased by 13.21% to ¥165,134,224.14 from ¥190,270,285.88 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 64.65% to ¥201,396,071.60 from ¥122,315,522.86 in the previous year[3] - Net profit for Q1 2022 was CNY 450,961,686.24, compared to CNY 353,809,542.16 in Q1 2021, reflecting an increase of approximately 27.5%[17] - The total comprehensive income attributable to the parent company was ¥160,637,650.03, down from ¥187,456,684.57 in the previous year[18] - Basic and diluted earnings per share for Q1 2022 were both ¥0.0640, down from ¥0.0738 in Q1 2021[18] Cash Flow - The net cash flow from operating activities was negative at -¥474,078,022.77, a decrease of 297.28% compared to ¥240,313,176.47 in the same period last year[3] - Operating cash inflow for Q1 2022 was ¥4,512,263,714.73, an increase of 39.7% from ¥3,227,571,032.48 in Q1 2021[20] - The net cash flow from investing activities was -¥1,619,628,525.05, worsening from -¥743,676,752.25 in Q1 2021[21] - The net cash flow from financing activities increased by 331.25% to ¥1,480,420,170.03, compared to -¥640,178,152.90 in the previous year[7] - The total cash and cash equivalents at the end of Q1 2022 were ¥5,495,402,220.54, a decrease from ¥5,237,194,072.65 at the end of Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥40,892,985,826.83, an increase of 10.30% from ¥37,073,195,202.73 at the end of the previous year[3] - The total liabilities of the company reached CNY 24,679,292,484.36, compared to CNY 21,414,358,734.26, reflecting an increase of approximately 15.6%[16] - The company's total liabilities increased, with contract liabilities rising by 40.62% to ¥1,330,965,240.60, reflecting increased customer prepayments[6] - Long-term borrowings rose to CNY 2,273,303,311.20, compared to CNY 1,934,186,143.00 in the previous year, an increase of approximately 17.6%[16] Research and Development - R&D expenses increased by 84.81% to ¥254,263,898.68 from ¥137,578,237.58 year-on-year, indicating a significant investment in research and development[7] - Research and development expenses for Q1 2022 were CNY 254,263,898.68, up from CNY 137,578,237.58, indicating an increase of about 84.5%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 284,509, with the largest shareholder holding 15.04% of shares, equating to 387,882,121 shares[9] - The total number of shares held by the top ten shareholders with unrestricted shares amounts to 387,882,121 shares for the largest shareholder, representing a significant concentration of ownership[11] Legal and Investment Activities - The company is currently involved in legal proceedings regarding a civil ruling that allows for the preservation of assets valued at approximately RMB 670.72 million[13] - The company signed a cooperation agreement to invest in a lithium battery anode material project with an annual production capacity of 200,000 tons in Dali, Yunnan[12] - A new investment cooperation agreement was signed for a project to produce 40,000 tons of silicon-based anode materials in Shenzhen[13] Other Financial Metrics - The company's cash and cash equivalents at the end of the reporting period amount to approximately RMB 6.31 billion, down from RMB 6.58 billion at the beginning of the year, representing a decrease of about 4.14%[14] - The total current assets increased to approximately RMB 27.00 billion, up from RMB 23.88 billion, indicating a growth of about 13.5%[14] - Accounts receivable rose to approximately RMB 4.06 billion, an increase of about 20.5% from RMB 3.37 billion at the beginning of the year[14] - Inventory levels increased to approximately RMB 11.40 billion, up from RMB 10.14 billion, reflecting a growth of about 12.4%[14] - The company reported a decrease in tax expenses to CNY 83,457,942.85 from CNY 92,160,543.37, a reduction of approximately 9.2%[17] - The company reported a decrease in other comprehensive income attributable to the parent company, which was -¥4,496,574.11 compared to -¥2,813,601.31 in Q1 2021[18]